Fig. 4: Ex vivo micro-tumour responses correlate to clinical patient responses. | npj Precision Oncology

Fig. 4: Ex vivo micro-tumour responses correlate to clinical patient responses.

From: Ex vivo 3D micro-tumour testing platform for predicting clinical response to platinum-based therapy in patients with high-grade serous ovarian cancer

Fig. 4

A Correlation between actual and predicted CA125 decay rates. Correlation: 0.77 (CI95: 0.63 - 0.87), r-squared:0.59, LOOCV correlation:0.71, LOOCV r-squared:0.51). B Predicted CA125 decay rates for GCIG response categories (CR complete response, PR partial response, SD stable disease). Statistical significance was determined using a Mann-Whitney U test (** p < 0.01). C Correlation of change target lesion size (%) between diagnosis and interval (before debulking) to predicted CA125 decay by ex vivo testing. Pearson correlation coefficient between predictedCA125 decay and the change in target lesion size: -0.49 (CI95: 0.83 - -0.07). D PFS rates for patients having high and low predicted CA125 decay rates (median split). Left graph: all patient included in the clinical correlation cohort (n = 37), middle: patients that did not receive interval debulking (n = 11), right: patients that did receive interval debulking (n = 26).

Back to article page